15 Nov Immunotherapy Tofacitinib Can Halt Alopecia Areata

Posted at 12:18h in Annals Internal Medicine, Author Interviews, Dermatology, Immunotherapy by

MedicalResearch.com Interview with:
Dr. Morton Scheinberg, MD, PhD
From Hospital Israelita Albert Einstein and Hospital AACD,
São Paulo, and
Clinica Dermatosineida, Maringa, Parana, Brazil.

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: That universal hair loss associated with a localized autoimmune reaction on the cells involved with the hair follicles can be halted with tofacitinib.

MedicalResearch.com: What should readers take away from your report?

Response: This is an opportunity for innovative oral therapy for alopecia universalis.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Additional real life experience and clinical trial to be done.

MedicalResearch.com: Is there anything else you would like to add?

Response: This new therapy does not apply to baldness of endocrine origen which is more common

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Annals of Internal Medicine November 14 2016

Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Morton Scheinberg, MD, PhD; Sineida Berbert Ferreira, MD

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]

Last Updated on November 15, 2016 by Marie Benz MD FAAD

356
Tags:
, ,